Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Ilodecakin (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARTIST 1; Sequoia
- Sponsors ARMO Biosciences
- 09 Oct 2017 According to an ARMO BioSciences media release, Joseph Leveque, M.D. will lead this trial.
- 20 Apr 2017 According to an ARMO BioSciences media release, results from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 29 Mar 2017 According to an ARMO BioSciences media release, first patient has been dosed.